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Human  respiratory  syncytial  virus  (RSV)  is  a leading  cause  of  severe  respiratory  disease  and  hospital-
izations  in  infants  and  young  children.  It also  causes  signiﬁcant  morbidity  and  mortality  in  elderly  and
immune  compromised  individuals.  No licensed  vaccine  currently  exists.  Parainﬂuenza  virus 5  (PIV5)  is
a  paramyxovirus  that  causes  no  known  human  illness  and  has  been  used  as  a  platform  for vector-based
vaccine  development.  To evaluate  the  efﬁcacy  of PIV5  as a RSV  vaccine  vector,  we  generated  two  recom-
binant  PIV5  viruses  – one  expressing  the  fusion  (F) protein  and  the other  expressing  the  attachment
glycoprotein  (G)  of RSV strain  A2  (RSV  A2).  The  vaccine  strains  were  used  separately  for single-dose  vac-
cinations  in  BALB/c  mice.  The  results  showed  that  both  vaccines  induced  RSV  antigen-speciﬁc  antibodyarainﬂuenza  virus 5 responses,  with  IgG2a/IgG1  ratios  similar  to  those  seen  in wild-type  RSV  A2  infection.  After  challeng-
ing  the  vaccinated  mice  with  RSV  A2,  histopathology  of  lung  sections  showed  that  the  vaccines  did  not
exacerbate  lung  lesions  relative  to RSV  A2-immunized  mice.  Importantly,  both  F  and  G vaccines  induced
protective  immunity.  Therefore,  PIV5  presents  an  attractive  platform  for vector-based  vaccines  against
RSV  infection.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Respiratory syncytial virus is the most important cause of pedi-
tric respiratory virus infection, and is a major cause of morbidity
nd mortality among infants, immune compromised individuals,
nd the elderly [1]. In the early 1960s, vaccination of infants with a
ormalin-inactivated RSV vaccine not only failed to protect against
SV disease during the following RSV season, but some vaccinees
eveloped enhanced disease upon natural infection, resulting in
ncreased rates of severe pneumonia and two deaths [2]. In the
ntervening years, a number of different approaches have been
valuated, including subunit vaccines, vectored vaccines, and live
ttenuated vaccines. However, there remains no licensed RSV vac-
ine. Therefore, there is a pressing need for a safe and effective
accine for RSV.
Parainﬂuenza virus 5 (PIV5), a negative-sense, non-segmented,
ingle-stranded RNA virus, is a good viral vector for vaccine
∗ Corresponding author. Tel.: +1 706 542 2855.
E-mail  address: bhe@uga.edu (B. He).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.049
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
development. PIV5 is safe, as it infects a large number of mam-
mals without being associated with any disease except canine
kennel cough [3–7]. Humans have been exposed to PIV5 [8–10],
likely due to the wide use of kennel cough vaccines containing live
PIV5, which dogs can shed after vaccination [11]. Given anti-PIV5
immunity in humans, anti-vector immunity may  be a problem. Our
recent studies indicate that pre-existing immunity to PIV5 does
not negatively affect immunogenicity of a PIV5-based vaccine in
dogs, demonstrating that pre-existing immunity is not a concern for
using PIV5 as a vector. This result is consistent with the report that
neutralizing antibodies against PIV5 do not prevent PIV5 infection
in mice [13].
PIV5  has been used as a platform for developing vector-based
vaccines against other viruses. A single-dose immunization of PIV5
expressing the rabies virus glycoprotein G protects mice against
lethal rabies virus challenge [14]. Additionally, a single-dose inoc-
ulation of PIV5 expressing hemagglutinin (HA) or the NP protein
of inﬂuenza virus protects against lethal H5N1 challenge in mice
[15,16]. Importantly, intranasal administration of PIV5 is effective
for eliciting robust mucosal immune responses [17], and is there-
fore ideal for vaccinating against respiratory pathogens.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Since an anti-RSV-F monoclonal antibody has been used to con-
rol RSV infection, it may  be possible to develop an RSV vaccine
y targeting RSV-F. Although several studies have implicated the
 protein in RSV disease pathogenesis [18–21], prophylactic or
herapeutic treatment with a monoclonal antibody (mAb 131-2G)
peciﬁc to RSV-G mediates virus clearance and decreases leukocyte
rafﬁcking and IFN- production in the lungs of RSV-infected mice
22–26]. In this study, we have tested the efﬁcacies of recombinant
IV5 expressing RSV-F (rPIV5-RSV-F) or RSV-G (rPIV5-RSV-G) as
otential vaccines in mice.
. Materials and methods
.1.  Cells and viruses
BSR-T7  cells were maintained in Dulbecco’s modiﬁed Eagle
edium (DMEM) containing 10% fetal bovine serum (FBS), 10%
ryptose phosphate broth (TPB), 100 IU/mL penicillin, 100 g/mL
treptomycin (1% P/S; Mediatech Inc., Manassas, VA, USA), and
00 g/mL G418 sulfate (Mediatech, Inc.). MDBK, BHK21, and Vero
ells were maintained in the same media without TPB or G418.
To  construct the plasmids for rescuing rPIV5-RSV-F or rPIV5-
SV-G, the coding sequence of the green ﬂuorescent protein (GFP)
ene in the BH311 plasmid [27], containing GFP between HN and L
f the full-length PIV5 genome, was replaced with the RSV-F or RSV-
 gene, respectively. rPIV5-RSV-F and rPIV5-RSV-G were rescued
s described previously [27]. PIV5, rPIV5-RSV-F and rPIV5-RSV-G
ere grown in MDBK cells as described previously [27]. RSV A2
nd rA2-Luc (RSV A2 expressing Renilla luciferase) were grown in
ero cells as previously described [21].
.2. Immunoprecipitation and Western blots
Immunoprecipitation (IP) was performed as previously
escribed [27]. A549 cells were infected with rPIV5-RSV-F or
SV A2 in 6-cm dishes. After 18–20 h, the cells were starved
nd metabolically labeled with 35S-Met and 35S-Cys for 3 h. The
ells were lysed with whole-cell extraction buffer (WCEB; 50 mM
ris–HCl [pH 8], 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 2 mM
GTA, 10% glycerol) [28] and immunoprecipitated with anti-RSV-F
ntibody. The IP products were resolved on a 10% SDS-PAGE
el and visualized using a Typhoon 9700 Phosphorimager (GE
ealthcare Life Sciences, Piscataway, NJ, USA).
To examine RSV-G protein expression, rPIV5-RSV-G-infected
DBK  cells and RSV A2-infected A549 cells were lysed with WCEB.
he lysates were processed and resolved by SDS-PAGE as described
efore. The proteins were transferred onto a polyvinylidene diﬂuo-
ide (PVDF) membrane and detected using mouse anti-RSV-G
ntibody (1:2000 dilution) as previously described [14].
.3.  Recombinant PIV5 growth curves and plaque assays
6-Well plates of Vero cells were infected with rPIV5-RSV-F,
PIV5-RSV-G, or PIV5 at a MOI  = 5 or 0.01. 100 L samples of super-
atant were collected at 0, 24, 48, 72, 96, and 120 h post-infection.
irus was quantiﬁed by plaque assay as described in Chen et al.
14].
.4. Immunization of mice
All  animal experiments were performed according to the proto-
ols approved by the Institutional Animal Care and Use Committee
t the University of Georgia. Six-to-eight week-old female BALB/c
ice (Harlan Laboratories, Indianapolis, IN, USA) were anesthetized
y intraperitoneal injection of 200 L of 2, 2, 2-tribromoethanol
n tert-amyl alcohol (Avertin). Immunization was performed by (2014) 3050–3057 3051
intranasal administration of 106 PFU of rPIV5-RSV-F, rPIV5-RSV-
G, or RSV A2 in a 50 L volume. Negative controls were treated
intranasally with 50 L of PBS.
Three weeks post-immunization, blood was collected via the
tail vein for serological analysis. Four weeks post-immunization, all
mice were challenged intranasally with 106 PFU of RSV A2 in a 50 L
volume. Four days later, lungs were collected from 5 mice per group
to assess viral burden. The lungs of the other 5 mice in each group
were perfused with 10% formalin solution and sent for histology.
To detect neutralizing antibody titers, mice were immunized as
described above and terminally bled 4 weeks post-immunization.
2.5. ELISAs measuring total RSV antigen-speciﬁc IgG, IgG1 and
IgG2a
RSV-F  and RSV-G-speciﬁc serum antibody titers were measured
by ELISA. Immulon® 2HB 96-well microtiter plates were coated
with 100 L of puriﬁed RSV-F or G protein at 1 g/mL in PBS [21]
and incubated overnight at 4 ◦C. Two-fold serial dilutions of serum
were made in blocking buffer (5% nonfat dry milk, 0.5% BSA in wash
buffer; KPL, Inc., Gaithersburg, MD,  USA). 100 L of each dilution
was transferred to the plates and incubated for one hour at room
temperature. After aspirating the samples, the plates were washed
three times with wash buffer. Secondary antibody was diluted
1:1000 [alkaline phosphatase-labeled goat anti-mouse IgG (KPL,
Inc.) or horseradish-peroxidase-labeled goat anti-IgG1 or IgG2a
(SouthernBiotech, Birmingham, AL, USA)] in blocking buffer. 100 L
of diluted secondary antibody was  added to each well, and the
plates were incubated for one hour at room temperature. After aspi-
ration, the plates were washed and developed with 100 L of pNpp
substrate or SureBlue Reserve TMB  substrate (KPL, Inc.) at room
temperature. The OD was  read at 405 nm or 450 nm using a BioTek
Epoch microplate reader. The endpoint antibody titer was deﬁned
as the highest serum dilution at which the OD was greater than two
standard deviations above the mean OD of the naïve serum.
2.6.  Neutralizing antibody assay
Two-fold serial dilutions of serum were made starting at a 1:10
dilution with Opti-MEM supplemented with 1% BSA and 5% guinea
pig complement (Sigma–Aldrich, St. Louis, MO,  USA). The diluted
serum was incubated with 100 TCID50 of RSV A2 expressing Renilla
luciferase (rA2-Rluc) for one hour at 37 ◦C, 5% CO2 [29]. The serum
and virus mixture was  transferred to conﬂuent monolayers of Vero
cells in 96-well plates and incubated for 18 h at 37 ◦C, 5% CO2. The
cells were then lysed with 70 L/well of Renilla lysis buffer for
20 min  while shaking on an orbital shaker. The lysates were trans-
ferred to V-bottom plates and clariﬁed by centrifugation at 2000 × g
for 5 min  40 L of clariﬁed lysate was transferred to Costar® white
96-well assay plates (Corning, Inc., Corning, NY, USA) and read
using a GloMax® 96 microplate luminometer (Promega). Neutral-
izing antibody titers were reported as the highest serum dilution
at which the luminescence measurement was lower than that of
50 TCID50 of rA2-Rluc based on a standard curve. Cells treated with
100 TCID50 of UV-inactivated rA2-Luc were the negative control.
2.7.  Titration of RSV from mouse lungs
Mouse lungs were harvested aseptically into gentleMACS M
tubes (Miltenyi Biotec Inc., Auburn, CA, USA) containing 3 mL  of
Opti-MEM with 1% BSA and stored on ice. Lungs were homogenized
at 4 ◦C using the Protein 01 program of a gentleMACS Dissociator
(Miltenyi Biotec Inc.) and then centrifuged at 3000 × g for 10 min.
RSV titers in the supernatants were determined using plaque assay
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Fig. 1. Generation of rPIV5-RSV-F and rPIV5-RSV-G. (A) Schematic of rPIV5-RSV-F
and  rPIV5-RSV-G. NP, nucleoprotein; V, V protein; P, phosphoprotein; M,  matrix
protein;  F, fusion protein; SH, small hydrophobic protein; HN, hemagglutinin-
neuraminidase protein; L, RNA-dependent RNA polymerase; RSV-F, respiratory
syncytial  virus fusion protein; RSV-G, respiratory syncytial virus G attachment gly-
coprotein. (B) RSV-F expression in rPIV5-RSV-F-infected A549 cells was detected
by immunoprecipitation. rPIV5-RSV-F-infected cells were starved and labeled with
35S-Met and 35S-Cys at 18–20 h post-infection. Proteins from cell lysate were
immunoprecipitated with mouse anti-RSV-F antibody, and expression was visual-
ized by 35S incorporation. Lysate from RSV A2-infected A549 cells was the positive
control.  Lysate from rPIV5-GFP-infected A549 cells was the negative control. (C)
Detection of RSV-G expression by Western blot. MDBK cells were infected with
rPIV5-RSV-G and lysate was immunoblotted with mouse anti-RSV-G antibody.
Lysate  from RSV A2-infected A549 cells was the positive control. Lysate from rPIV5-
GFP-infected MDBK cells was the negative control. (D) Single-cycle growth curves
of rPIV5-RSV-F and rPIV5-RSV-G in Vero cells. Vero cells were infected at a MOI  = 5.
Aliquots of cell culture supernatant were collected at 24-h intervals for 120 h. (E)
Multi-cycle growth curves of rPIV5-RSV-F and rPIV5-RSV-G in Vero cells. Vero cells
were infected at a MOI  = 0.01. Aliquots of cell culture supernatant were collected at052 S.I. Phan et al. / Vacc
s described in Johnson et al., except the media was  0.8% methyl-
ellulose in Opti-MEM with 2% FBS, 1% P/S [30].
.8. Histology
Four days post-challenge, the lungs from the mice were perfused
ith 1 mL  of 10% formalin and then immersed in 10% forma-
in for at least 24 h. The formalin-ﬁxed lungs were transferred to
0% ethanol, embedded in parafﬁn wax, sectioned, and stained
ith hematoxylin and eosin. A pathologist scored the sections in
 group-blind fashion for perivascular cufﬁng, interstitial pneu-
onia, bronchiolitis, alveolitis, vasculitis and pleuritis. The lesions
ere scored on a scale of 0 to 4, with 0 indicating no lesions and 4
ndicating severe lesions.
.9.  Statistical analysis
Statistical  analysis was  performed using Graphpad Prism soft-
are version 5.04 for Windows (Graphpad Software, La Jolla, CA,
SA). Analysis of variance (ANOVA) and Tukey multiple comparison
ests were used to analyze total serum IgG, IgG1 or IgG2a antibody
iters and lung viral loads. Unpaired, two-tailed t-test was  used to
nalyze neutralizing antibody titers. Histology data was analyzed
sing the Kruskal–Wallis test.
. Results
.1. Construction and characterization of recombinant
IV5-based RSV vaccine viruses
RSV-F and RSV-G genes from RSV A2 were cloned into a plasmid
ontaining the PIV5 backbone. The genes were inserted in between
he HN and L genes, and the viruses were rescued by methods
reviously described (Fig. 1A) [31]. RSV-F expression in rPIV5-RSV-
-infected cells was conﬁrmed by immunoprecipitation with an
SV-F-speciﬁc monoclonal antibody (Fig. 1B). Expression of RSV-G
n rPIV5-RSV-G-infected cells was shown by Western blot using an
SV-G-speciﬁc monoclonal antibody (Fig. 1C). RSV-G expressed in
PIV5-RSV-G-infected cells displayed both wild-type size and gly-
osylation pattern. RSV-F and RSV-G were detected in rPIV5-RSV-F
nd rPIV5-G virions respectively (data not shown).
Single-step and multi-step growth rates of rPIV5-RSV-F, rPIV5-
SV-G and PIV5 were compared. In the single-step growth curve,
oth rPIV5-RSV-F and rPIV5-RSV-G displayed slightly delayed
rowth kinetics at 24 h compared to PIV5, and grew to similar,
hough slightly decreased, titers by 48 h (Fig. 1D). This growth delay
as also evident in the multi-step growth curve at 24 h, but both
he rPIV5-RSV-F and rPIV5-RSV-G grew to titers similar to PIV5 by
8 h (Fig. 1E). Therefore, growth kinetics of the rPIV5-RSV-F and
PIV5-RSV-G were similar to that of PIV5, although with a slight
elay at early time points and a slight decrease in ﬁnal viral titer.
.2.  Immunization with recombinant PIV5-based RSV vaccine
iruses  induces RSV antigen-speciﬁc antibody responses
Total serum IgG antibody titers to RSV were measured 21 days
ost-vaccination. Mice immunized with rPIV5-RSV-F developed F-
peciﬁc serum IgG antibodies, although to a lesser degree (∼2-fold
ower) than RSV A2-immunized mice (Fig. 2A and B). Interestingly,
ice vaccinated with rPIV5-RSV-G developed G-speciﬁc antibody
iters slightly higher (∼2-fold) than those seen in mice immunized
ith RSV A2 (Fig. 2C and D). Mice treated with PBS had no detectable
SV-speciﬁc antibodies (Fig. 2A–D).
Immunization with the recombinant vaccine viruses induced
SV antigen-speciﬁc IgG2a/IgG1 antibody ratios similar to those
bserved in RSV A2-immunized mice. Overall, RSV-F-speciﬁc IgG1
24-h intervals for 120 h. Plaque assays were performed in BHK21 cells to determine
the  virus titer at each time point. Growth curve samples were assayed in duplicate.
Error bars represent the standard error of the mean.
S.I. Phan et al. / Vaccine 32 (2014) 3050–3057 3053
Fig. 2. Immunization with rPIV5-RSV-F and rPIV5-RSV-G induces RSV antigen-speciﬁc IgG antibody responses in mice. Naïve BALB/c mice were treated with PBS or immunized
intranasally with 106 PFU of rPIV5-RSV-F, rPIV5-RSV-G, or RSV A2. Sera were collected at 3 weeks post-immunization. (A) Anti-RSV-F IgG antibody curves were generated
by ELISA using serially diluted sera. (B) RSV-F-speciﬁc IgG antibody endpoint titers were determined based on the values in (A). (C) Anti-RSV-G IgG antibody curves were
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gG antibody conjugated to alkaline phosphatase. Each group consisted of 10 mice. E
epresent  the mean antibody titer of each group. Statistical signiﬁcance was  determ
nd IgG2a titers were lower in rPIV5-RSV-F-immunized mice com-
ared to the RSV A2-immunized mice (Fig. 3A). RSV-G-speciﬁc IgG1
nd IgG2a titers in rPIV5-RSV-G and RSV A2-immunized mice were
imilar (Fig. 3B). Mean RSV-F-speciﬁc IgG2a/IgG1 ratios in rPIV5-
SV-F and RSV A2-vaccinated groups were 13 and 5, respectively,
ith no signiﬁcant difference between the two groups (Fig. 3C).
ean RSV-G-speciﬁc IgG2a/IgG1 ratios of groups vaccinated with
PIV5-RSV-G or RSV A2 were 0.49 and 0.48, respectively (Fig. 3D).
he IgG2a/IgG1 ratios induced by the rPIV5 vaccine candidates did
ot differ signiﬁcantly from those observed in RSV A2 infection,
hich is known to generate balanced IgG2a/IgG1 responses.
.3.  Immunization with rPIV5-RSV-F generates RSV-neutralizing
ntibodies
A  complement-enhanced microneutralization assay was  per-
ormed to determine if serum antibodies induced by immunization
ere able to neutralize RSV A2 expressing Renilla luciferase (rA2-
luc) in vitro. By 28 days post-immunization, mice immunized with
PIV5-RSV-F or RSV A2 generated neutralizing antibodies against
A2-Rluc. The antibody titers of the rPIV5-RSV-F-immunized group
id not differ signiﬁcantly from the titers of the RSV A2-immunizedd on the values in (C). Serum IgG was detected in (A) and (C) using goat anti-mouse
ars in (A) and (C) represent standard error of the mean. Horizontal lines in (B and D)
by ANOVA and Tukey multiple comparison tests. * P < 0.05. LOD, limit of detection.
group.  No neutralizing activity was  detected in the sera of rPIV5-
RSV-G-immunized mice (Fig. 4).
3.4. Recombinant PIV5-based RSV vaccine viruses induce
protective immunity in the mouse lung
Four days post-challenge, RSV A2 titers were measured in the
lungs to assess the efﬁcacy of the recombinant vaccine viruses in
reducing viral burden. Mice vaccinated with either rPIV5-RSV-F
or rPIV5-RSV-G had no detectable challenge virus in the lungs.
In the RSV A2-immunized group, one mouse had a viral titer of
90 PFU/lung, while all other mice in the group had no detectable
virus. Mice with PBS had an average viral titer of 4.5 × 103 PFU/lung
(Fig. 5). Therefore, immunization with the vaccine candidates
induced potent immunity against RSV A2 challenge.
3.5. Mice immunized with recombinant PIV5-based RSV vaccine
viruses  or RSV A2 display similar lung lesionsLung histology was performed to determine if immunization
with the recombinant vaccine viruses affected RSV-induced lung
pathology. At low magniﬁcation, tissue from mice vaccinated with
3054 S.I. Phan et al. / Vaccine 32 (2014) 3050–3057
Fig. 3. Immunization with rPIV5-RSV-F and rPIV5-RSV-G induce IgG1 and IgG2a antibody responses similar to RSV A2 infection. Naïve BALB/c mice were treated with PBS
or  immunized intranasally with 106 PFU of rPIV5-RSV-F, rPIV5-RSV-G, or RSV A2. Sera were collected 3 weeks post-immunization. (A and B) RSV-F (A) and RSV-G-speciﬁc
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gG2a/IgG1 ratios were calculated using values in (A) and (B), respectively. IgG1 and I
atios. Each group consisted of 5 mice. Solid horizontal lines represent the mean of 
SV A2 or the rPIV5 viruses showed similar levels of inﬂammatory
nﬁltrates 4 days post-challenge. Lung tissue from the mock-
accinated mice was the least inﬂamed (Fig. 6A–D), suggesting that
accinated animals had likely generated immune responses to RSV
hallenge.
At high magniﬁcation, the inﬂammation in the mice vaccinated
ith RSV A2 or the recombinant vaccine viruses was character-
zed most prominently by perivascular cufﬁng (Fig. 7A and B). The
eukocytes surrounding the pulmonary blood vessels consisted of
ostly lymphocytes and macrophages, with few neutrophils and
osinophils. Mild-to-moderate interstitial pneumonia (Fig. 7A and
) and little-to-no bronchiolitis (Fig. 7A and D) was observed in
ll groups. Tissue sections were also scored for alveolitis, pleuritis,
nd vasculitis (Fig. 7E–G). There were no signiﬁcant differences in
he histopathology scores of mice vaccinated with the recombinant
accine viruses relative to the RSV A2-vaccinated controls..  Discussion
The most advanced area of investigation for RSV vaccine candi-
ates is live attenuated viruses. These viruses have several beneﬁts:ondary antibodies conjugated to HRP. (C and D) RSV-F (C) and RSV-G-speciﬁc (D)
antibodies in the sera were quantiﬁed using standard curves to generate IgG2a/IgG1
roup. Dotted horizontal lines indicate a ratio of 1.
(1)  enhanced RSV disease has not been observed either after natu-
ral infection or vaccination with live attenuated viruses [32–34]; (2)
live attenuated RSV vaccines induce balanced immune responses
that more closely match natural immunity compared with subunit
or inactivated vaccines [35,36]; (3) intranasal vaccination with live
attenuated viruses should induce better local immunity compared
with intramuscular injection of subunit vaccines. Live attenuated
RSV vaccines have been in development for several decades, using
a combination of cold passage (cp) and chemical mutagenesis to
induce temperature sensitivity (ts). A number of cpts RSV vaccine
candidates have been tested clinically. The cpts 248/404 candidate
was sufﬁciently attenuated in adults and sero-negative children
and tested in 1 to 3-month-old infants. However, cpts 248/404
caused nasal congestion in these infants, an unacceptable adverse
effect [32]. More recently, the advent of reverse genetics sys-
tems for RSV, whereby infectious virus is derived from cDNAs, has
allowed the development of live attenuated RSV vaccine candidates
encoding speciﬁc combinations of attenuating mutations and dele-
tions of nonessential viral genes. RSV lacking NS2 (rA2NS2) was
tested in clinical trials as a vaccine for the elderly since it was less
attenuated in chimpanzees than cpts 248/404. It was shown to be
S.I. Phan et al. / Vaccine 32 (2014) 3050–3057 3055
Fig. 4. Immunization with rPIV5-RSV-F generates RSV-neutralizing antibodies.
Naïve  BALB/c mice were treated with PBS or immunized intranasally with 106 PFU
of rPIV5-RSV-F, rPIV5-RSV-G, or RSV A2. At 4 weeks post-immunization, sera were
collected and tested for RSV-neutralizing activity using a microneutralization assay.
Neutralizing antibody titers were deﬁned as the highest dilution of sera at which
the  luminescence measurement of the sample was  less than that of 50 TCID50 of
rA2-Rluc using a standard curve. Each group consisted of 4–5 mice. All samples
were  assayed in duplicate. Horizontal lines represent the mean antibody titer of
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Fig. 5. Immunization with rPIV5-RSV-F and rPIV5-RSV-G generates protective
immunity  against RSV A2 challenge. Naïve BALB/c mice were treated with PBS or
immunized intranasally with 106 PFU of rPIV5-RSV-F, rPIV5-RSV-G, or RSV A2. At
4 weeks post-immunization, mice were challenged with 106 PFU of RSV A2. At 4
days post-challenge, lungs were harvested and viral load was  determined by plaque
assay in Vero cells. Each group consisted of 5 mice. Solid horizontal lines repre-
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fach group. Statistical signiﬁcance was determined by unpaired, two-tailed t-test.
, P < 0.05. LOD, limit of detection.
ver-attenuated in adults but under-attenuated in children, a con-
raindication for testing in infants [37]. Subunit and other synthetic
accines have shown only moderate immunogenicity in clinical
rials, even with the development of newer adjuvant regimens.
ectored vaccines expressing RSV F and/or G have been generated
ig. 6. Low-magniﬁcation images of post-challenge lung lesions in mice treated with PBS 
ith  PBS or immunized intranasally with 106 PFU of rPIV5-RSV-F, rPIV5-RSV-G, or RSV A2
 days post-challenge, lungs were harvested and ﬁxed with 10% formalin. Lung sections 
A) Lung section from a mouse treated with PBS. (B) Lung section from a RSV A2-immunize
rom  a rPIV5-RSV-G-immunized mouse.sent  the geometric mean of each group. Statistical signiﬁcance was determined by
ANOVA and Tukey multiple comparison tests. *, P < 0.05. LOD, limit of detection.
based on paramyxoviruses such as Sendai virus (SeV), Newcastle
disease virus (NDV), and a chimeric recombinant bovine parain-
ﬂuenza virus 3 (PIV3) expressing human PIV3 F/HN and RSV-F
(MEDI-534). Sendai virus expressing RSV-F or G protected the lower
respiratory tract (LRT) of cotton rats against RSV infection [38,39].
SeV-RSV-F also conferred LRT protection in African green monkeys
or immunized with RSV A2, rPIV5-RSV-F or rPIV5-RSV-G. BALB/c mice were treated
. Four weeks after immunization, mice were challenged with 106 PFU of RSV A2. At
were stained with hemotoxylin and eosin. Images were taken at 4x magniﬁcation.
d mouse. (C) Lung section from a rPIV5-RSV-F-immunized mouse. (D) Lung section
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Fig. 7. High-magniﬁcation images of post-challenge lung lesions in mice treated
with  PBS or immunized RSV A2, rPIV5-RSV-F or rPIV5-RSV-G. BALB/c mice were
treated with PBS or immunized intranasally with 106 PFU of rPIV5-RSV-F, rPIV5-
RSV-G,  or RSV A2. Four weeks after immunization, mice were challenged with
106 PFU of RSV A2. Four days after challenge, lungs were harvested and ﬁxed with
10% formalin. Lung sections were stained with hemotoxylin and eosin. (A) Images
in the far-left column show perivascular cufﬁng. Images in the middle column
show  interstitial pneumonia. Images in the far-right column show bronchiolitis.
Each  image is from a representative mouse in each group. Images of lung lesions
were  taken at 40× magniﬁcation. (B–G) Lung sections were scored in a group-blind
fashion  on a scale of 0–4 for perivascular cufﬁng (B), intersititial pneumonia (C),
bronchiolitis (D), alveolitis (E), vasculitis (F), and pleuritis (G). Each group consisted
of  5 mice. Horizontal lines represent the mean of each group. Statistical signiﬁcance
was  determined using the Kruskal–Wallis test. *, P < 0.05. (2014) 3050–3057
[40]. Immunization of mice with NDV expressing RSV-F was  only
modestly effective, reducing RSV burden in lungs by approximately
1 log10 [41]. MEDI-534 was attenuated and safe in clinical trials,
but it was only minimally immunogenic in adults and children
[42]. Furthermore, the vaccine candidate genome was unstable,
with mutations observed in vivo and in vitro [43,44]. Thus, while
many RSV vaccine candidates have been researched extensively, an
important public health gap remains for RSV disease prevention.
This  work demonstrated that PIV5-based RSV vaccine candi-
dates provide a promising alternative for RSV vaccine development.
Single-dose immunization with rPIV5-RSV-F or rPIV5-RSV-G
induced potent immunity against RSV challenge in mice. Impor-
tantly, the recombinant vaccine viruses did not exacerbate lung
lesions relative to the RSV A2-immunized controls. Natural infec-
tion with RSV does not lead to enhanced disease upon reinfection,
in contrast to immunization with formalin-inactivated RSV [45].
Inﬂammation in the lung tissue of mice immunized with the vac-
cine candidates was likely due to the induction of host immunity
in response to RSV challenge.
Serum neutralizing antibodies were generated in rPIV5-RSV-F-
immunized mice, suggesting that the vaccine candidate induces
a functional, systemic humoral response against RSV. Immuniza-
tion with rPIV5-RSV-G did not generate neutralizing antibodies,
but reduced viral burden in the lungs. The mechanism is unclear,
but rPIV5-RSV-G immunization may  generate protective antibodies
that are non-neutralizing in vitro. In the case of the RSV-G sub-
unit vaccine candidate, BBG2Na, passively transferred serum from
immunized mice reduced lung viral burden in recipient mice at
dilutions negative for neutralizing activity [46]. Other groups have
also shown that neutralizing activities of RSV-G or RSV-F-speciﬁc
antibodies in vitro do not necessarily correlate with lung protection
in vivo [47–49].
In  summary, PIV5 is safe, stable, efﬁcacious, cost–effective to
produce, and overcomes pre-existing anti-vector immunity. In this
work, we  have shown that PIV5-based RSV vaccine candidates have
the potential to be effective RSV vaccines, providing an additional
option for RSV vaccine development.
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